Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

Kei Ohnuma; Bart L Haagmans; Ryo Hatano; V Stalin Raj; H. Mou; Satoshi Iwata; Nam H Dang; Berend Jan Bosch; Chikao Morimoto

doi:10.1128/JVI.02448-13

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

Kei Ohnuma, Bart L Haagmans, Ryo Hatano, V Stalin Raj, H. Mou, Satoshi Iwata, Nam H Dang, Berend Jan Bosch, Chikao Morimoto

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

Original language	English
Pages (from-to)	13892-9
Number of pages	8
Journal	Journal of Virology
Volume	87
Issue number	24
DOIs	https://doi.org/10.1128/JVI.02448-13
Publication status	Published - Dec 2013

Keywords

Antibodies, Monoclonal
Antibodies, Viral
Coronaviridae
Coronaviridae Infections
Dipeptidyl Peptidase 4
Epitope Mapping
Humans
Protein Binding
Protein Structure, Tertiary
Spike Glycoprotein, Coronavirus
Virus Internalization

Access to Document

10.1128/JVI.02448-13

Journal of Virology-2013-Ohnuma-13892.fullFinal published version, 2.02 MB

Cite this

@article{4aa6e254c442407a8ccfab6bbe446f3e,

title = "Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody",

abstract = "We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.",

keywords = "Antibodies, Monoclonal, Antibodies, Viral, Coronaviridae, Coronaviridae Infections, Dipeptidyl Peptidase 4, Epitope Mapping, Humans, Protein Binding, Protein Structure, Tertiary, Spike Glycoprotein, Coronavirus, Virus Internalization",

author = "Kei Ohnuma and Haagmans, {Bart L} and Ryo Hatano and Raj, {V Stalin} and H. Mou and Satoshi Iwata and Dang, {Nam H} and Bosch, {Berend Jan} and Chikao Morimoto",

year = "2013",

month = dec,

doi = "10.1128/JVI.02448-13",

language = "English",

volume = "87",

pages = "13892--9",

journal = "Journal of Virology",

issn = "0022-538X",

publisher = "American Society for Microbiology",

number = "24",

}

TY - JOUR

T1 - Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

AU - Ohnuma, Kei

AU - Haagmans, Bart L

AU - Hatano, Ryo

AU - Raj, V Stalin

AU - Mou, H.

AU - Iwata, Satoshi

AU - Dang, Nam H

AU - Bosch, Berend Jan

AU - Morimoto, Chikao

PY - 2013/12

Y1 - 2013/12

N2 - We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

AB - We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

KW - Antibodies, Monoclonal

KW - Antibodies, Viral

KW - Coronaviridae

KW - Coronaviridae Infections

KW - Dipeptidyl Peptidase 4

KW - Epitope Mapping

KW - Humans

KW - Protein Binding

KW - Protein Structure, Tertiary

KW - Spike Glycoprotein, Coronavirus

KW - Virus Internalization

U2 - 10.1128/JVI.02448-13

DO - 10.1128/JVI.02448-13

M3 - Article

C2 - 24067970

SN - 0022-538X

VL - 87

SP - 13892

EP - 13899

JO - Journal of Virology

JF - Journal of Virology

IS - 24

ER -

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

Abstract

Keywords

Access to Document

Fingerprint

Cite this